SAGE Therapeutics, Inc.

SAGE Therapeutics, Inc.

SAGE Therapeutics, Inc.

Overview
Date Founded

2010

Headquarters

215 1st Street,Cambridge, MA 02142

Type of Company

Public

Employees (Worldwide)

675

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at SAGE Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Chief Financial Officer & Treasurer

Senior Vice President, General Counsel, Secretary

Chief Scientific Officer

Chief Research Officer

Chief Medical Officer

Chief Business Officer

Senior Vice President-People & Organizational Strategy

Senior Vice President-Regulatory Affairs & Policy

Senior Vice President, Technical Operations

Board of Directors

Co-Founder at Third Rock Ventures LLC

Senior Vice President & Chief Financial Officer at Alkermes Plc

Former Venture Partner at Third Rock Ventures LLC

Chief Executive Officer at Cerecor, Inc.

Director, President & Chief Executive Officer at SAGE Therapeutics, Inc.

President & Chief Executive Officer at UroGen Pharma Ltd.

Venture Partner at ARCH Venture Partners

President & Chief Executive Officer at Elucida Oncology, Inc.

Clinical Practice at Stanford VA Hospital

Paths to SAGE Therapeutics, Inc.
Potential Connections via
Relationship Science
You
SAGE Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm's in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech's investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Details Hidden

Eventide Asset Management is a leader in faith-based on socially responsible investing value-oriented, socially responsible investment manager.The Eventide Fund seeks to provide long-term capital appreciation. It invests primarily in a broad range of equity securities and is not restricted by market-cap. The fund may invest, without limitation, in securities in companies domiciled outside the US either directly or through ADRs. Historically, the fund has had a small/mid-cap growth emphasis. The fund tends to overweight in the healthcare sector.The Eventide Healthcare & Life Sciences Fund is a non-diversified mutual fund investing in the healthcare and life sciences sector. The fund uses bottom-up fundamental research to find companies with the potential to appreciate in value as positive data is released regarding clinical trials and FDA feedback, and market acceptance of products. Under normal market conditions, the fund invests at least 80% of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.The Eventide Multi-Asset Income Fund seeks current income while maintaining the potential for capital appreciation. The fund has the flexibility to achieve its investment objective by primarily investing in a broad universe of income-producing securities. These securities include debt and equity securities of companies in the U.S. and other markets around the world. These securities may include but are not limited to common stocks, real estate investment trusts (REITs), business development companies, yieldcos, master limited partnerships (MLPs), preferred stocks, corporate bonds, government agency bonds, certificates of deposit, municipal bonds, inflation-linked bonds, mortgage-backed securities, options, exchange traded notes, ETFs, and other investment companies (including mutual funds and closed-end funds). The Fund may invest up to 15% of its net assets in companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid.The Global Dividends Opportunities Fund Seeks to provide dividend income and long-term capital appreciation with a secondary objective of dividend growth. Is is a globally diversified equity fund representing Eventide's \"best ideas\" approach to dividend-paying stocks. The fund invests globally across industry sectors and market capitalizations through both traditional and non- traditional equity income categories.

Details Hidden

Great Point Partners seeks to achieve positive excess returns by investing in publicly traded biotechnology, healthcare information technology, medical device, medical diagnostic and specialty pharmaceutical companies. The firm focuses on creating a balanced portfolio comprised primarily of companies that are undervalued by the public markets. Great Point's hedge funds employ a bottom-up research-driven approach to investing in the securities of undervalued, publicly-traded healthcare companies. They target fast-growing, technology- driven small-cap companies. In addition, Great Point manages private equity funds that invest in private, primarily profitable, lower middle-market, growing healthcare companies.

Recent Transactions
Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Details Hidden

SAGE Therapeutics, Inc. issued USD Common Stock

Transaction Advisors
Escrow Agent

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onSAGE Therapeutics, Inc. issued USD Common Stock

Clients

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Key Stats and Financials As of 2019
Market Capitalization
$1.49B
Total Enterprise Value
$2.7B
Earnings Per Share
$-13.38
Revenue
$6.87M
Net Profit
$-680M
EBITDA
$-706M
EBITDAMargin
-10.3K%
Total Debt
$37.1M
Total Equity
$945M
Enterprise Value Sales
392.89x
TEVNet Income
-3.97x
Debt TEV
0.01x
Investors
Details Hidden

Ecor1 Capital manages the EcoR1 Capital Fund LP, a fundamental long/short equity hedge fund focusing on investment opportunities in the biotechnology sector. The firm employs an innovative, process-driven approach that is based on a value philosophy which attempts to manage risk in the volatile biotechnology sector. The fund focuses on outliers not typically analyzed as part of value based diligence; human capital in addition to deep scientific and financial analysis. Ecor1 Capital is committed to going beyond the usual monetary investment in companies and engages directly with management to identify opportunities for efficiencies and growth, and where necessary, invests their own human capital resources to help mediate much of the risk that is inherent in the sector. The goal of combining this innovative perspective and process is generation of uncorrelated returns relative to the biotechnology sector and to the overall market.

Details Hidden

ARCH Venture Partners focuses on seed and early-stage investments in start-up technology companies, with a particular interest in the life sciences, the physical sciences and information technology. Their life sciences investments focus on biotechnology, pharmaceuticals, medical instrumentation and informatics. Their physical sciences investments focus on companies that are pioneering technology with a range of commercial applications in chemicals/materials, electronics/instrumentation and medical instrumentation industries. The firm's focus within the information technology sector includes electronics/hardware, information, infrastructure/software and commerce. ARCH Venture Partners invests primarily in companies located in the southwestern, Midwestern, eastern seaboard and northwestern sections of the US. The firm exits most of their investments through IPOs or private sales.

Details Hidden

FMR may use a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. They may also use general macro-economic analysis as a component of its security analysis methods. In addition to relying on public financial statement information, the firm may use extensive corporate visits and interviews with issuer management teams in conducting research. When it comes to the management of the client assets according to the investment objectives, FMR may use a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR's or its affiliates' central funds. They may also engage in securities lending to parties such as broker-dealers or other institutions.

Suppliers
Washington University in St. Louis Publishing | St. Louis, MO

The mission of Washington University in St. Louis is the promotion of learning — learning by students and by faculty. Teaching, the transmission of knowledge, is central to our mission, as is research, the creation of new knowledge. Faculty — composed of scholars, scientists, artists and members of the learned professions — serve society by teaching; by adding to the store of human art, creativity, understanding, and wisdom; and by providing direct services, such as health care. The university offers more than 90 programs and almost 1,500 courses leading to bachelor's, master's and doctoral degrees in a broad spectrum of traditional and interdisciplinary fields, with additional opportunities for minor concentrations and individualized programs.

Ligand Pharmaceuticals, Inc. Medical Support Services | La Jolla, CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

University of California Investment Services & Portfolio Management | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Competitors
Marinus Pharmaceuticals, Inc. Pharmaceuticals - Radnor, PA

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by SAGE Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of SAGE Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and SAGE Therapeutics, Inc..